Business Context and Reporting Period
This Form 8-K Current Report was filed by Silexion Therapeutics Corp on June 3, 2025, regarding events occurring on May 28, 2025. The Company, incorporated in the Cayman Islands with principal offices in Ramat-Gan, Israel, is an emerging growth company. Its ordinary shares (SLXN) and warrants (SLXNW) are listed on the Nasdaq Global Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial threshold referenced is a listing requirement:
- Shareholders' Equity Requirement: The Company intends to apply for a transfer to the Nasdaq Capital Market, which requires a minimum of $2.5 million in shareholders' equity.
Material Changes and Events
The primary event reported is the Company's response to a Nasdaq delisting notice:
- Delisting Notice: On May 22, 2025, Nasdaq issued a notice regarding non-compliance with listing rules requiring a minimum Market Value of Listed Securities (MVLS) of $50 million and a minimum Market Value of Publicly Held Shares (MVPHS) of $15 million.
- Compliance Period Expired: The 180-day compliance period to rectify these deficiencies ended on May 19, 2025, without the Company meeting the standards.
- Appeal Filed: On May 28, 2025, the Company requested a hearing with the Nasdaq Hearings Panel. Consequently, the delisting process has been stayed, and securities will continue trading under symbols SLXN and SLXNW pending the hearing.
- Hearing Date: The hearing is scheduled for June 26, 2025.
Outlook, Strategy, and Risks
Management Strategy:
- The Company plans to request a transfer of its listing from the Nasdaq Global Market to the Nasdaq Capital Market.
- The Company may request additional time from the Hearings Panel to meet the Equity Standard of $2.5 million required for the Capital Market.
- There is no assurance that the appeal will be successful or that the transfer to the Capital Market will be approved.
- There is no assurance that the Company will meet the $2.5 million equity requirement within any extension period granted.
- Failure to resolve these issues could result in the delisting of the Company's securities.
The filing contains forward-looking statements regarding the appeal outcome and listing transfer. These are subject to risks and uncertainties, and the Company assumes no obligation to update them.
Investor Verification Checklist
- Verify the outcome of the Nasdaq Hearings Panel hearing scheduled for June 26, 2025.
- Confirm whether the Company successfully transfers its listing to the Nasdaq Capital Market.
- Review the Company's most recent financial statements (e.g., Form 10-K filed March 18, 2025) to determine if current shareholders' equity meets the $2.5 million threshold.
- Monitor trading status of SLXN and SLXNW for any suspension or delisting notices following the hearing.